Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease
NCT07576010Phase 1Active, not recruiting
- Sponsor
- Daihong Liu
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Daihong Liu. Primary endpoint: Graft-Versus-Host Disease-Free, Relapse-Free Survival at 1 year. Started Jan 2025; status: active, not recruiting.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07576010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07576010.